CGON (CG Oncology) Total Receivables: $1.28 Mil (As of Mar. 2026)


CGON CG Oncology Inc CGON
12 GF Score
Price $70.40
! 5 Warning Signs
View Full Analysis

What is CG Oncology Total Receivables?

CG Oncology CGON -0.75% 12 Total Receivables is $1.28 Mil as of Mar. 2026. GuruFocus rates CGON with a GF Score™ of 12/100. The stock has 5 warning signs investors should review.

CG Oncology's Total Receivables for the quarter that ended in Mar. 2026 was $1.28 Mil.

CG Oncology Total Receivables Historical Data

* Premium members only.

The historical data trend for CG Oncology's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CG Oncology Total Receivables Chart

CG Oncology Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
0.00 0.30 0.09 0.00 0.69

CG Oncology Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.35 0.56 0.52 0.69 1.28
CGON
12GF Score
CG Oncology Inc CGON
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CG Oncology Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $1.28 Mil mean?
CG Oncology (CGON) has a Total Receivables of $1.28 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on CG Oncology and its competitors.
Is CG Oncology's Total Receivables too high?
CG Oncology's current Total Receivables is $1.28 Mil. Overall, CG Oncology has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does CG Oncology's Total Receivables compare to COGT and SRRK?
CG Oncology's Total Receivables of $1.28 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on CG Oncology and its competitors. CG Oncology's current Total Receivables is $1.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CG Oncology stock overvalued right now?
CG Oncology (CGON) has a current Total Receivables of $1.28 Mil. The current Total Receivables is $1.28 Mil. CG Oncology's overall GF Score™ is 12/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For CG Oncology (CGON), the current Total Receivables is $1.28 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CG Oncology Business Description

Address 400 Spectrum Center Drive, Suite 2040, Irvine, CA, USA, 92618
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
12GF Score

Get the complete analysis for CGON

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$70.40
Price